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Molecular Mechanisms in Meeting Review
Cell-Mediated Cytotoxicity
Alessandro Moretta The activation of members of cystein protease in-
terleukin-1b converting enzyme (ICE) family, now calledDepartment of Biomedical Science
the caspase family (Alnemri et al., 1996), is believed toand Biotechnologies
be required for cell death, at least as to its nuclearUniversity of Brescia
manifestations. GraB can cleave and thus activate cas-25100 Brescia
pases, leading tocell death. This pathway was examinedand Institute of Histology
by C. Bleackley and colleagues, who showed GraB±University of Genoa
induced caspase 3 activation and its further processing16132 Genoa
in target cells (Darmon et al., 1995). However, the possi-Italy
bility that this occurs via an upstream caspase was sug-
gested by J. P. Medema (GermanCancer Center, Heidel-
Intense research has been devoted over the past two berg, Germany) and P. Krammer (Inst. fur Immunologie
decades to the elucidation of the precise molecular und Genetik, Heidelberg, Germany), who demonstrated
mechanisms by which cytotoxic T lymphocytes (CTLs) that caspase inhibitors that do not block caspase 3 do
and natural killer (NK) cells recognize and kill target cells. block its processing induced by CTL. Further results led
Both issues have been recently discussed at the EMBO them to conclude that the caspase FLICE (see below)
Workshop on Cell-Mediated Cytotoxicity held in Kerk- is a likely substrate for GraB. P. Henkart and colleagues
rade, The Netherlands, on April 5±9, 1997, organized by presented similar data showing that GraB can process
R. L. H. Bolhuis and C. J. M. Melief. procaspases leading to their proteolytic activation and
The Two Major Pathways of to apoptotic nuclear damage (Sarin et al., 1997). How-
Cell-Mediated Cytotoxicity ever, they also showed that caspase inhibitors block
Recent studies have demonstrated that two indepen- nuclear relocalization and DNA fragmentation but not
dent mechanisms account for the cytotoxicity mediated 51Cr release, strongly suggesting that GraB can also
by CTLs (Kagi et al., 1994; Lowin et al., 1994): the first cleave a noncaspase substrate thereby leading to mem-
is consequent to the secretion of their characteristic brane damage. There might well be additional functional
molecules in thegranules beyond just perforin and GraB.electron-dense cytoplasmic granules whereas the sec-
Indeed, Trapani and colleagues showed that the overex-ond is represented by a nonsecretory pathway based on
pression of Bcl-2 protects cells subjected to perforinthe interaction of CD95L (Fas ligand) with the apoptosis-
and GraB from DNA fragmentation but not cells sub-inducer CD95 (Fas) molecule expressed on target cells.
jected to cytotoxic cells or to purified granules. Impor-So far, the mechanism by which NK cells mediate lysis
tantly, M. Simon and colleagues (Max-Planck-Institut,of NK-susceptible target cells appears to be mostly, if
Freiburg, Germany) showed that although in vitro± or exnot exclusively, based on granule exocytosis.
vivo±derived CTL and NK cells (Ebnet et al., 1995) fromThe initiation of apoptosis by granule exocytosis is
double knock out GraA2/2 GraB2/2 mice displayed re-the result of action of two types of molecules released
duced granule-mediated cytotoxicity in terms of nuclearinto the extracellular space after contact between ef-
lesions, they could still induce 51Cr release. This stronglyfector and target cells: the pore-forming perforin and
suggests that release of 51Cr can either be mediated bythe lymphocyte-specific granule serine esterase gran-
perforin alone, or involves some other granule compo-zyme B (GraB). These molecules interact in the target
nent as well, possibly another granzyme.cells to reproduce all of the features of CTL or NK-
As to the major Fas-based mechanism of cytotoxicity,induced apoptosis. These include nuclearchanges such
it is now clear that oligomerization, probably trimeriza-as chromatin condensation and finally DNA fragmen-
tion, of CD95 is necessary to attract intracellularly pre-tation.
formed signaling molecules. The cytoplasmic tail of Fas
The mechanism of entry into target cells of GraB and
contains a motif called the ªdeath domain.º This domain
the mechanism by which it induces nuclear damage has
can interact with the corresponding death domain of
been investigated by several groups. Thus, C. Froelich the adaptor molecule Fas-associated protein with death
(Northwestern University, Evanston, Illinois) C. Bleack- domain (FADD), thus recruiting FADD to the plasma
ley (University of Alberta, Edmonton, Canada), J. Trapani membrane. FADD, in turn, interacts with the caspase
(Austin Research Institute, Victoria, Australia), and P. FLICE through ªdeath effector domains.º These do-
Henkart (National Cancer Institute, NIH, Bethesda, mains are located at the amino terminus of FLICE and
Maryland) studied in detail the respective roles of GraB at the carboxyl terminus of FADD. This interaction leads
and perforin (Froelich et al., 1996; Jans et al., 1996; Shi to the assembly of the receptor-associated death-
et al., 1997). It has been shown that GraB is endo- inducing signaling complex (DISC). The DISC-bound
cytosed by target cells independently of perforin, possi- FLICE induces the proteolytic activation of other mem-
bly through saturable high affinity cell surface binding bers of the caspase family resulting ultimately in
sites. In the absence of added perforin, GraB shows apoptosis (Boldin et al., 1996; Muzio et al., 1996).
a cytoplasmic localization. On the other hand, when A new family of virus-encoded inhibitors termed viral
perforin is added (and presumably enters cells, through FLICE-inhibitory proteins (vFLIPs) that interferes with
an as yet undefined mechanism) in about half of the apoptosis signaled via the CD95 death receptor was
cells, GraB relocalizes to the nucleus. These cells that described (J. Tschopp, University of Lausanne, Switzer-
land). These inhibitors, which are found in particular inshow GraB relocalization undergo apoptotic death.
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a series of g-herpes viruses, allow the virus to undergo by the ªmissing self hypothesisº (Ljunggren and Karre,
1990). Different types of inhibitory receptors specific forreplication before the host cells finally succumb. The
vFLIPs are characterized by twodeath-effector domains groups of HLA-C (p58.1 and p58.2), HLA-B (p70), or
HLA-A (p70±140) alleles have been molecularly identi-which, similar to FLICE, are able to interact with FADD,
thus competing for the recruitment of FLICE induced by fied and cloned (reviewed by Moretta et al., 1996). They
belong to the Ig superfamily and are characterized bythe oligomerization of the CD95 receptor (Thome et al.,
1997). two or three extracellular domains. These receptors are
distributed in a clonal fashion and each NK cell ex-Cell death signaling pathways related to the Fas and
TNF. R1 pathways also exist in invertebrates. A molecule presses at least one inhibitory NKR for self HLA±class
I alleles. In addition, activating forms of HLA-C-specificcalled ªreaperº was shown by H. Steller and his col-
leagues (White et al., 1994) to be necessary and suffi- receptors have been described (p50.1, p50.2, and p50.3)
that differ from the corresponding inhibitory receptorscient to induce cell death in Drosophila during develop-
ment. Homology was found between the death domains in their transmembrane and cytoplasmic portions. More
recently, a second class of MHC class I±specific recep-and reaper (Golstein et al., 1995). Some periodicity, such
as several successive leucine residues, separated by 7 tors has been demonstrated in human NK cells (Moretta
et al., 1994; Sivori et al., 1996; Lazetic et al., 1996). Theseresidues, was detected both in death domains of
TNF-R1 and in reaper. Amino acid alignment showed NKR display a broad specificity for different HLA-class
I molecules although they appear to bind preferentiallythat the middle third of reaper was more homologous
to the death domains of TNF-R1 and DR3 (Chinnaiyan to certain groups of HLA-alleles (those belonging to the
Bw6 supertypic specificity) and poorly to others (Bw4et al., 1996) than to the death domains of Fas. Interest-
ingly, the former are bound by TNF-R1-associated pro- alleles). They are formed by CD94 molecules that associ-
ate with different members of the NKG2 molecular familytein with death domain (TRADD), the latter by FADD.
Thus, both the degree of homology and the connecting to form either inhibitory (CD94/NKG2A) or activating
NKR (CD94/NKG2C) (A. Moretta, University of Brescia,molecules are consistent with the existence of subfami-
lies of death domains. Reaper would be evolutionarily Italy). Both CD94 and NKG2A molecules are type 2 trans-
membrane proteins belonging to the C-type lectin su-closer to one of these subfamilies (P. Golstein, INSERM-
CNRS, Marseille-Luminy, France). perfamily (reviewed by Lopez-Botet et al., 1997). Re-
markably, both NKG2A and inhibitory NKR of the IgStudies using gene knockout animals (E. R. Podack,
University of Miami, Florida) indicated that mice defi- superfamily are characterized by intracytoplasmic im-
munoreceptor tyrosine based inhibition motifs (ITIM),cient for both perforin and Fas ligand expression died
of severe pancreatitis, with atrophic uterus and ovary which are essential for SHP-1 phosphatase activation
and induction of inhibitory signals (reviewed by ReÂnardinfiltrated with cells from a particular T cell subpopula-
tion. This might be interpreted as a requirement for both et al., 1997). Because of the molecular structure, the
broad specificity and the functional property, CD94/or either the Fas or the perforin pathway for the elimina-
tion of antigen-presenting cells; thus when the latter are NKG2 complexes could represent the human counter-
part of the murine Ly49 family of MHC-class I-specificnot eliminated, persistentantigen presentation may lead
to continuous T cell activation and tissue damage (auto- NK receptors. In view of the recent evolution of the HLA-
class I system, it is likely that those NKR belongingreactive T cells?).
A novel class of Fas-activated serine/threonine ki- to the Ig superfamily have evolved more recently than
C-type lectin NKR to adapt to the polymorphism emerg-nases (FASTs) that phosphorylate the RNA binding pro-
tein TIA-1 during stress-induced apoptosis has been ing in the HLA class I system (reviewed by Valiante et
al., 1997). This receptor strategy allows the NK cell sys-described by P. Anderson (Dana Farber Cancer Institute,
Boston, Massachusetts). TIA-1 is a component of a sig- tem to sense even single allelic loss as it may occur in
tumor or virally infected cells. In this context, CD94/naling cascade that may regulate entry into apoptosis
(Taupin et al., 1995). TIA-1 binds to oligopyrimidine NKG2 complexes would represent an ancestral type of
MHC-class I recognition strategy.tracts found in the 59 untranslated regions of mRNAs
subject to stress-induced translational arrest. Some of Inhibitory NKR are also expressed on a small subset
of human T lymphocytes (reviewed by Moretta et al.,these mRNAs encode ribosomal subunits and survival
factors such as IGF-II, hence proteins that are essential 1996). NKR1 T cells have been detected in peripheral
blood, spleen, tonsil, and lymph nodes but not in thymusfor cell growth. In response to stress, TIA-1 accumulates
in the cytoplasm where it aggregates with free and and cord blood. Surface marker analysis has revealed
that NKR1 T cells always express a memory phenotype;ER-associated ribosomes at ªstress bodies.º The re-
cruitment of selected Bcl-2 family members to these moreover, in several normal donors analyzed, they are
characterized by a skewed TCRVb repertoire. Crosslink-aggregates has been postulated to regulate entry into
apoptosis. ing of NKR leads to inhibition of different TCR-depen-
dent and TCR-independent (e.g., NK-like cytotoxicity)MHC-Class I±Specific NK Cell Receptors
In recent years, the molecular mechanisms by which NK T cell functions. The inhibitory effect exerted on TCR-
mediated functions has important implications. Thus,cells lyse or fail to lyse target cells have been elucidated.
NK cells express receptors (NKR) that recognize MHC the expression of inhibitory NKR may result in functional
impairment of specific CTLs. Preliminary data wouldclass I molecules on target cells. The interaction be-
tween NKR and MHC class I leads to inhibition of cyto- suggest that this phenomenon may occur in tumor
(Ikeda et al. 1997) or virally infected patients (L. Moretta,lytic activity thus preventing lysis of normal, MHC class
I positive, target cells. This mechanism was predicted University of Genoa, Italy). The fact that antigen-specific
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CTLssimultaneously express TCRand NKR, both recog- TAP-deficient RMA-S target cells showed that ªemptyº
class I molecules do not protect cells from Ly49C1 NKnizing HLA-class I molecules but mediating opposite
signals, offers new perspectives in our appreciation of cells. On the other hand, the same cells are protected
after incubation in the presence of peptides bindingthe regulation of T cell responses and provides new
clues for understanding the immunopathologic events to Kb. This is in line with previous experiments on the
Ly49A receptors displaying a similar peptide-depen-involved in certain diseases. Data were also presented
that are compatible with the existence of additional, still dency (Correa and Raulet, 1995). Similar to the human
NKR, a dichotomy of function between the various mem-unknown, inhibitory receptors in alloantigen-stimulated
T cells. These cells were inhibited in their cytolytic func- bers of the Ly49 family has been demonstrated also
in mice. In particular, cross-linking of Ly49A or Ly49Ction by a set of HLA-C alleles corresponding to those
recognized by the p58.2 receptors; however, they did resulted in thyrosine phosphorylation of the receptors
while this was not observed after cross-linking of Ly49Dnot react with the presently available anti-p58.2 MAbs
(K. Falk, University of Munich, Germany). (J. Ortaldo, National Cancer Institute, Frederick, Mary-
land). These results are consistent with both the knownRecent studies indicated that the nonclassical HLA-
class I molecule HLA-G, which is the only class I mole- structural and functional characteristics of these Ly49
molecules, in that Ly49A, C, and G2 have ITIM motifscule expressed by trophoblast cells, is recognized by
inhibitory receptors expressed on human NK cells (Paz- containing phosphorylation sites while Ly49D does not
contain this inhibitory motif. Therefore, despite signifi-many et al., 1996; Munz et al., 1997). This issue has been
discussed by H. G. Rammensee (University of Tubingen, cant divergence in their extracellular domains, human
p58/p50 receptors and murine Ly49 receptors are likelyGermany) who presented data suggesting that the re-
ceptors involved in HLA-G recognition may be related to share common signaling properties (reviewed by ReÂ -
nard et al., 1997).to the HLA-Bw4-specific p70 NKR (or NKAT-3). These
data are in conflict with those reported by J. Stroming- Viral Strategies to Elude CTL or NK
Cell-Mediated MHC Recognitioner's group (Pazmany et al. 1996) showing that HLA-G
recognition is mediated by the HLA-C-specific p58 re- It is well known that T lymphocytes, primarily MHC class
I-restricted CD81 CTL, play a major role in the controlceptors. Further studies are required to elucidate the
precise contribution of the various NKR to HLA-G recog- of virus infections. Some DNAviruses, on the otherhand,
have evolved strategies to interfere with the process ofnition since other groups have recently shown that
HLA-G is recognized by the CD94/NKG2A complex and MHC/viral peptide presentation to CTLs (reviewed by
Spriggs, 1996). The recent understanding of the mecha-not by p58 or p70 receptors (Pende et al., 1997; Perez-
Villar et al., 1997). nisms involved in antigen presentation made possible
the unraveling of several of the molecular mechanismsThe need for inhibitory NKR to prevent NK-mediated
lysis of self cells implies the existence of one or more by which viruses interfere with MHC class I antigen pre-
sentation. However, while downregulation of cell surfaceactivating receptors that interact with ligand(s) ex-
pressed on target cells. However, limited information is expression of MHC class I molecules (the so-called
ªstealth strategyº) will prevent the CTL-mediated lysisavailable on the surface receptors that are involved in
NK cell triggering. Thus the search for new molecules of infected cells, it should render them susceptible to
NK-mediated lysis (Karre and Welsh, 1997) (see below).capable of triggering the NK-mediated cytotoxicity is
now becoming crucial for defining the molecular mecha- The first known example of viral protein interfering
with MHC class I pathway is the E19 protein of adenovi-nisms involved in NK cell activation/inactivation. In this
context, a new molecule termed p46, has been identified rus (Andersson et al., 1985). Since E19 molecule inter-
acts with MHC class I molecules at the ER level, classthat induces strong NK cellactivation uponcross-linking
by specific MAbs (S. Sivori, University of Genoa, Italy). I molecules do not reach the cell surface, but they are
retrieved from the Golgi together with E19 molecules.The p46 molecule is selectively expressed on all human
NK cells, resting or activated, and the levels of cytolytic Not all the HLA-class I alleles bind equally well to E19,
which therefore preferentially inhibits the expression ofactivity of different NK clones against HLA-negative
targets correlates with the number of p46 molecules certain alleles (thus rendering cells susceptible to lysis
by NK cell subsets expressing appropriate NKR). Otherexpressed at their cellsurface. p46 is clearly distinguish-
able from p50 molecules (i.e., the HLA-C-specific acti- viruses that inhibit the MHC class I expression include
members of the Herpes virus family. For example, thevating receptors) because of its molecular size, cell dis-
tribution, and distinct specificity. It may represent a Herpes simplex (HSV) encoded ICP47 molecule (York
et al., 1994) binds to TAP1 and TAP2 in the cytosol andreceptor for non-HLA ligands expressed on both HLA1
and HLA2 target cells. The precise definition of the p46 prevents the TAP-mediated binding and transport of
peptides. The human cytomegalovirus (HCMV) employsligand will be possible upon cloning of this new receptor.
In mice, all the MHC class I-specific receptors charac- different strategies to inhibit HLA class I expression
(Fruh et al., 1997). The US6 glycoprotein resides in theterized so far belong to the Ly49 molecular family (re-
viewed by Yokoyama and Seaman, 1993). Most of them ER and interferes with the peptide translocation, but not
with their binding to TAP molecules. US2 and US11are inhibitory receptors including Ly49A specific for Dd
and DK, Ly49C specific for Kb (and some H-2d) and (Wiertz et al., 1996) prevent the HLA class I heavy chains
from leaving the ER compartment and shuttle them backLy49G2 specific for Dd and Ld. Analysis of the peptide
dependency in the NKR-mediated recognition of MHC into the cytosol where they are degraded by protea-
somes. US3 protein (Ahn et al., 1996) is expressed verymolecules revealed that Ly49C-mediated recognition is
strictly peptide-dependent. Indeed, studies employing early during HCMV infection, as early as virus-encoded
Cell
16
transcription factors, binds to class I molecules and respectively. In renal cancer, two types of CTL were
isolated, one detecting subtle changes in MHC expres-prevents their export to the surface. Consequently, in
the course of HCMV infection, HLA-class I molecules sion on tumor cells and the other showing MHC-
restricted, RCC-specific recognition of common RCCare first retained and then degraded, suggesting that
US3 represents the first line of viral interference, fol- determinants. These CTL families of T cells specifically
accumulateat the tumor site and are highly homologous.lowed by US11 and, possibly, by other US proteins (U.
Koszinowski, Max von Pettenkofer Institut, Munchen, In cervical cancer, HPV-16- and 18E6/E7-specific CTL
(see below) were identified in peripheral blood in lowGermany). It is interesting to note that NK cells play
an important role in controlling both HSV and HCMV frequency, but in higher frequencies in draining lymph
nodes and tumor infiltrating lymphocytes (TIL). R. E.infections. However, a potential mechanism to escape
the NK cell recognition can be the expression of a Toes (University of Leiden, The Netherlands) succeeded
in generating tumor-specific CTL by in vitro vaccinationb2-binding protein with a structural homology to MHC
class I heavy chain (ªdecoy strategyº). This protein, with recombinant adenoviruses (rAd) encoding tumor-
derived CTL epitopes (human adenovirus type 5 earlyÐtermed UL18, also binds peptides (Beck and Barrell,
1988; Fahnestock et al., 1995). Rather than interfering region 1A (Ad 5E1A), Ad5E1B and human papilloma virus
type 16E7 oncoproteins) in a string-of-bead fashion.substantially with antigen presentation to T cells, UL18
has been shown to function by protecting HCMV- The synthetic minigene-encoded CTL epitopes are pro-
cessed and presented to tumor-specific CTL. rAd-infected cells against NK cell lysis (reviewed by Reyburn
et al., 1997). Recent experiments showed that UL18 immunized mice were protected against otherwise lethal
challenge with tumor cells transformed by the relevanttransfection into HLA class I negative target cells con-
ferred to these cells resistance to NK-mediated lysis. oncoproteins.
The possible use of minor histocompatibility antigensThe broad specificity CD94/NKG2A receptor appears to
be responsible for binding UL18. Therefore HCMV has as a target for CTL-mediated specific recognition of
leukemic cells (Graft versus leukemia [GvL]) has beenevolved two complementary strategies to avoid identifi-
cation of infected cells by both CTLs and NK cells. A emphasized. This approach would allow the elimination
of the unwanted graft versus host diseases (GvHDs),corollary of the fact that HCMV has developed a mecha-
nism for evading NK-mediated detection is that NK cells which represents a frequent and serious complication
in bone marrow allograft. This approach, which is basedmust represent an important component of the cell-
mediated immune response to viral infection. on pulsingdendritic cells with the minor histocompatibil-
ity antigen HA-1 peptide, led to the generation of CTLsCytotoxic Lymphocytes in Immunotherapy
The development of strategies for the generation of ef- specific for HA-1-positive EBV transformed B cell lines
(R. M. Verdijk, Leiden University Hospital, The Nether-fective populations of antigen-specific CTL in immune
responses against tumor or virus-infected cells repre- lands). The use of viral ªstealthº genes (e.g., MCMV-
encoded proteins [Thale et al., 1995]) able to interferesents a major goal of studies of both basic and applied
immunology (Bolhuis et al., 1996). In this context, Eshhar with antigen presentation by MHC class I molecules (see
above) is currently being investigated in gene therapypioneered the field of constructing chimeric receptors
with tumor Ag specificity (Gross and Eshhar, 1992). T in an attempt to avoid recipients' CTL responses to the
vector or even to the therapeutic gene itself (W. Brune,lymphocytes expressing chimeric receptors with the ex-
tracellular antibody recognition unit, i.e., with antibody- Max von Pettenkofer-Institut, Munich, Germany). It ap-
pears that stealth genes themselves, outside the viraldictated specificity, efficiently lysed target cells ex-
pressing the relevant antigen. Originally, V heavy and V context, are able to protect cells from CTL-mediated
lysis by lowering MHC class I expression. By using anlight chains, in a single chain configuration, were linked
to the signal transducing g or z subunits (Eshhar et al., episomally replicating plasmid vector, which allows for
high and stable expression levels, cell lines were estab-1993). In a recent approach, the antibody recognition
unit was connected to a CD4-CD8 transmembrane lished that express one of these genes. In contrast to
the parental cell lines and mock transfected cells, thesestretch directly to the intracellular Syk protein-tyrosine
kinases. Making chimeric receptors with an NDF/He- cells displayed a virtually absent expression of MHC
class I molecules. Transfectants derived from murineregulin binding domain (Stancowski et al., 1993), it has
been possible to functionally recognize carcinoma cells tumor cell lines can now be analyzed in established
mouse model systems of tumorigenesis where CTLsoverexpressing the Erb family of oncogenic receptors.
R. L. H. Bolhuis and colleagues (Daniel den Hoed Cancer are known to influence tumor growth. If CTLs are not
generated, the next step will aim at the insertion of theCenter, Rotterdam, The Netherlands) presented data on
the construction of a single chain antibody/g chimeric therapeutic gene into the same vector in combination
with a ªstealthº gene. This therapeutic gene is then ex-receptor specific for renal cancer cells. They also
achieved efficient retroviral gene transduction in human pected to be nonimmunogenic.
Another important approach in cancer immunother-primary T cells and optimal in vitro expansion of gene-
modified T lymphocytes. This work is expected to result apy is focalized on the identification of tumor-associ-
ated antigens and their peptides, which can be rec-in a phase I clinical study using in vitro±expanded gene-
modified T cells expressing renal cell cancer (RCC)- ognized by specific CTL. These studies led to the
identification of numerous tumor-associated antigensspecific chimeric receptors for the treatment of meta-
static carcinoma. This approach may benefit from the (Coulie et al., 1994; Ikeda et al., 1997). Importantly, not
only the product of mutated genes are recognized, butdata presented by Drs. D. J. Schendel (Institut fur Immu-
nologie, Munich, Germany) and L. K. Borysiewicz (Col- also antigenic peptides derived from overexpressed
normal genes. Of particular relevance is the tumor sup-lege of Medicine, University of Wales, U.K.) who de-
scribed CTL specific for RCC or cervical cancer, pressor protein p53, because it is overexpressed in up
Meeting Review
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Impaired intracellular transport of class I MHC antigens as a possibleto 50% of all human malignancies. C. Melief (Dept. of
means for adenoviruses to evade immune surveillance. Cell 43,Immunohematology, Leiden Hospital, Leiden, The Neth-
215±222.erlands) reported on the generation of CTL recognizing
Beck, S., and Barrell, B.G. (1988). Human cytomegalovirus encodesa murine wild-type p53 peptide (Ropke et al., 1996) pre-
a glycoprotein homologous to MHC class I antigens. Nature 331,
sented by the H-2b MHC molecule by immunizing p53 269±272.
gene deficient (p532/2) mice with syngenic p53-overex- Boldin, M.P., Goncharov, T.M., Golstev, Y.V., and Wallach, D. (1996).
pressing tumor cells. Subsequent adoptive transfer of Involvement of MACH, a novel MORT/FADD-interacting protease, in
these CTL in tumor-bearing p531/1 nude mice caused Fas/APO-1 and TNF-receptor-induced cell death. Cell 85, 803±815.
complete and permanent tumor eradication. This oc- Bolhuis, R.L.H., Hoogenboom, H.R., and Gratama, J.W. (1996). Tar-
geting of peripheral blood T lymphocytes. Springer Semin. Immuno-curred in the absence of any demonstrable damage to
pathol. 18, 211±227.normal tissues. Thus, overexpression of p53 allows CTL
Chinnaiyan, A.M., O'Rourke, K., Yu, G.L., Lyons, R.H., Garg, M.,to discriminate between tumor cells and normal tissues,
Duan, D.R., Xing, L., Gentz, R., Ni, J., and Dixit, V.M. (1996). Signalmoreover widely expressed autologous molecules such
transduction by DR3, a death domain-containing receptor relatedas p53 can serve as a target for CTL-mediated immuno-
to TNFR and CD95. Science 274, 990±992.
therapy of tumors. In order to induce optimal tumor
Correa, I., and Raulet, D.H. (1995). Binding of diverse peptides to
antigen presentation and thus effective immune re- MHC class I molecule inhibits target cell lysis by activated natural
sponses, monocyte-derived dendritic cells (DCs) have killer cells. Immunity 2, 61±67.
been used as APC to induce primary immune responses Coulie, P.G., Brichard, V., Van Pel, A., Wolfel, T., Shneider, J., Traver-
against melanocyte differentiation antigens such as sari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J.P., et al.
(1994). A new gene coding for a differentiation antigen recognizedgp100, Melan A/Mart 1-, or tyrosinase-derived peptides
by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J.presented by HLA-A2.1. These in vitro±generated CTL
Exp. Med. 180, 35±42.were capable of lysing HLA-A2.1-positive tumor cells
Darmon, A.J., Nicholson, D.W., and Bleackley, R.C. (1995). Activa-expressing the appropriate antigen, suggesting that
tion of the apoptotic protease CPP32 by cytotoxic T-cell derived
these antigen-loaded DCscould provide useful immuno- granzyme B. Nature 377, 446±448.
therapeutic reagents for the induction of CTL responses Ebnet, K., Hausmann, M., Lehmann-Grube, F., Mullbacher, A., Kptf,
against autologous tumors (C. G. Figdor, Department of M., Lamers, R., and Simon, M.M. (1995). Granzyme-A-deficient mice
Tumor Immunology, Nijmegen Hospital, Nijmegen, The retain potent cell-mediated cytotoxicity. EMBO J. 14, 4230±4239.
Netherlands). Finally, evidence is now available on the Eshhar, Z., Waks, T., Gross, G., and Shindler, D.G. (1993). Specific
activation and targeting of cytotoxic lymphocytes through chimericpossibility of inducing peptide-specific down-regulation
single chains consisting of antibody-binding domains and theof T cell responses to intervene in autoimmune diseases
gamma or zeta subunits of the immunoglobulin and T-cell receptors.or graft rejections. Efficient tolerance inductionhas been
Proc. Natl. Acad. Sci. USA 90, 720±724.
achieved in unprimed animals by intraperitoneal admin-
Fahnestock, M.J., Johnson, J.L., Feldman, R.M., Neveu, J.M., Lane,
istration of peptides in incomplete Freund's adjuvants. W.S., and Bjorkman, P.J. (1995). The MHC class I homolog encoded
However, in the presence of peptide-specific memory by human cytomegalovirus binds endogenous peptides. Immunity
CTL, the same peptide treatment not only abrogates 3, 583±590.
the peptide-specific CTL activity but also has a general Froelich, C.J., Orth, K., Turbov, J., Seth, P., Gottlieb, R., Babior, B.,
Shah, G.M., Bleackley, R.C., Dixit, V.M., and Hanna, W. (1996). Newimmunosuppressive effect as a consequence of severe
paradigm for lymphocyte granule-mediated cytotoxicity. Targetimmunopathological damage in secondary lymphoid or-
cells bind and internalize granzyme B, but an endosomolytic agentgans. Peptide treatments of antigen-primed hosts there-
is necessary for cytosolic delivery and subsequent apoptosis. J.
fore may have deleterious and undesirable effects, Biol. Chem. 271, 29073±29079.
which has to be taken into account for therapeutic inter- Fruh, K., Ahn, K., and Peterson, P.A. (1997). Inhibition of MHC class
ventions (reviewed by Kagi et al., 1996) (H. Hengartner, I antigen presentation by viral proteins. J. Mol. Med. 75, 18±27.
University Hospital, Zurich, Switzerland). Golstein, P., Marguet, D., and Depraetere, V. (1995). Homology be-
tween Reaper and the cell death domains of Fas and TNFR1. Cell
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